{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obsessive-compulsive-disorder/supporting-evidence/pharmacological-versus-psychological-treatments-in-adults/","result":{"pageContext":{"chapter":{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults","depth":2,"htmlHeader":"<!-- begin field 0ca43c96-0270-46a7-ac71-0dc53a4b9b26 --><h2>Evidence on pharmacological versus psychological treatments in adults</h2><!-- end field 0ca43c96-0270-46a7-ac71-0dc53a4b9b26 -->","summary":null,"htmlStringContent":"<!-- begin item f9bcdc25-1e73-4207-82d3-8037c7e0a57a --><!-- begin field 7772a3cc-5d3b-4fff-aee4-4357ded127f3 --><p><strong>There is limited evidence from a systematic review commissioned by NICE (two randomized controlled trials [RCTs], n = 104) and one subsequent small RCT (n = 31) that exposure and response prevention (ERP) is superior to a selective serotonin reuptake inhibitor (SSRI) or clomipramine. A RCT (n = 31) found that people treated with behaviour therapy had a significantly better improvement in OCD symptoms compared to people treated with fluvoxamine. Another RCT (n = 158) found no difference between fluoxetine and group CBT.</strong></p><p>There was found to be no significant difference in the treatment of OCD with cognitive-behavioural therapy compared to sertraline or group behavioural therapy compared to fluoxetine in two other small RCTs. However, interpretation of results is limited by the small sample sizes.</p><ul><li><strong>ERP compared with clomipramine</strong><ul><li>The systematic review included two studies providing data on efficacy from 104 participants and on tolerability from 84 participants [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>]:<ul><li>ERP was superior to clomipramine in reducing obsessive-compulsive symptoms as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) or the Compulsive Checklist (standardized mean difference, SMD 20.67, 95% CI 21.16 to 20.17) and there was no significant difference between the groups for the likelihood of withdrawal.</li></ul></li></ul></li><li><strong>Behavioural therapy using ERP compared with fluvoxamine and control</strong><ul><li>A RCT (n = 31) compared three treatments: fluvoxamine, behavioural therapy using ERP, and control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Nakatani et al, 2005</a>]. The study reports that behavioural therapy showed 'significantly more reduction in total Y-BOCS score at the end of treatment' than the fluvoxamine group (p<0.01) and there were no withdrawals due to adverse effects. However, there were a number of methodological limitations.<!--_c2a0_0.0129_  --><ul><li>The method of randomization whereby the study coordinator randomly assigned participants to each group was potentially prone to bias; the use of randomization tables or computer-generated randomization would have been preferable.</li><li>The authors have not stated that results were analysed by intention-to-treat.</li><li>The starting dose of fluvoxamine (25 mg/day) was lower than usual starting dose of 50 mg/day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 65, 2013</a>].</li><li>Analysis of Variance (ANOVA, a multiple statistical test) was used but it is not clear how direct comparisons between the groups were made or whether the significance level was adjusted for multiple comparisons.</li></ul></li></ul></li><li><strong>Cognitive-behavioural therapy compared with sertraline</strong><ul><li>One small RCT (n = 56) failed to demonstrate a significant difference between cognitive-behavioural therapy and sertraline in either reduction of obsessive-compulsive symptoms as measured using Y-BOCS (p = 0.083, 95% CI not reported) or in the chance of improvement (reduction of 35% or more in Y-BOCS score) (p = 0.088, 95% CI not reported) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Sousa et al, 2006</a>]. There were three withdrawals from each group.</li></ul></li><li><strong>Group cognitive behavioural therapy compared with fluoxetine</strong><ul><li>In another RCT (n = 158) the clinical effectiveness of group cognitive behavioural therapy (GCBT) was compared with fluoxetine in adults using the Y-BOCS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Belotto-Silva et al, 2012</a>]. People were included if they had a baseline Y-BOCS scores of 16 or more. There was no statistically significant difference between both groups at the end of treatment for 12 weeks; the mean Y-BOCS scores decreased by 23.13% in the GCBT and 21.54% in the SSRI groups (p=0.875).</li></ul></li></ul><!-- end field 7772a3cc-5d3b-4fff-aee4-4357ded127f3 --><!-- end item f9bcdc25-1e73-4207-82d3-8037c7e0a57a -->","topic":{"id":"1f37cc0e-7573-58d0-a414-18973c123eae","topicId":"394f419d-3ab3-4fd3-85c7-7ae0c286d323","topicName":"Obsessive-compulsive disorder","slug":"obsessive-compulsive-disorder","lastRevised":"Last revised in June 2018","chapters":[{"id":"6854ef67-5e05-528c-afeb-b7680f464892","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0151ee13-83cc-5d06-9ce4-f03bc14a2d91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ac8f0f-9ef4-5778-82e7-0ee23afbaaf8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f571042f-c058-5f39-a22d-6901a3f9f4d0","slug":"changes","fullItemName":"Changes"},{"id":"31a9215e-18d0-5bd1-9341-846c7185dd16","slug":"update","fullItemName":"Update"}]},{"id":"39a21515-e7bc-515d-80d4-420f429a801f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9c01874c-054d-55f7-bc72-c5dc572bb4ce","slug":"goals","fullItemName":"Goals"},{"id":"bb1af94d-3d5a-5862-9e75-51cfd39e9e31","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"31dd33b1-cd86-57bc-84c1-206363cae677","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8aa2028a-8646-59f5-ac0b-c585d5f9474a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"96f32bee-6f1f-5862-8163-8f9adf02e81e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0c41f244-6591-5043-825b-f48000a19060","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"69296d43-e92e-51ad-803f-9b00dd4ef3eb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23304d59-7975-500a-9672-1d71c224d42b","slug":"definition","fullItemName":"Definition"},{"id":"75facf2a-3aa9-52ec-a213-c09d7c49305a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ef703cf4-f71d-53e8-ac6e-55fd3949af89","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16615ebe-7c11-54ea-8c8f-11b27bd84df0","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9c3a46c7-846c-5e14-9297-e80dfc82ffa5","slug":"complications","fullItemName":"Complications"}]},{"id":"9063127c-d315-5f06-81a4-0854a79730a5","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8e2a1f2f-09ef-5f73-a3ec-2aac2b0a90b7","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"d07d5382-3d58-534c-80b0-ebb514c9d790","fullItemName":"Management","slug":"management","subChapters":[{"id":"adfa1e25-924b-5e4d-b909-bbd62bfa3981","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs"},{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine"}]},{"id":"34094942-974d-50ae-b83e-52a2243c1e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"06ebd4e9-a6ff-5645-8bf1-4a06d03e073b","slug":"psychological-treatments-in-adults","fullItemName":"Psychological treatments in adults"},{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults"},{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults"},{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults"}]},{"id":"ed477751-4d36-5e3b-bfcb-60739e1daea7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6e26607d-6208-5c71-a5ee-ba2bd8567311","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"700ff2f4-6d6b-5235-8301-91ad6701f206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"20682403-8c70-5f97-86c4-1f8234b42261","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9242ca74-0efb-54f8-9cb4-267acc46dc6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8a264e61-1997-5859-8b1d-e1d859ffa219","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c91ccb0b-b8e6-5c2a-ab14-79b9eff3e63a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"34094942-974d-50ae-b83e-52a2243c1e47","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}